Trial Scorecard: REDEFINE 1 and 2 Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE 1 Trial? Seeking Alpha In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Mediocre results from the Phase 3a trial for cagrilintide and semaglutide #CagriSema in obesity and type 2 diabetes. Average weight loss at week 68 was 13.7% in the CagriSema group and 3.4% Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet